LifeStance Health Group (NASDAQ:LFST) Given New $13.00 Price Target at JPMorgan Chase & Co.

LifeStance Health Group (NASDAQ:LFST) had its target price increased by JPMorgan Chase & Co. from $9.00 to $13.00 in a report issued on Friday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Several other equities analysts have also weighed in on the stock. Wall Street Zen lowered shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. KeyCorp boosted their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Weiss Ratings raised shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday. The Goldman Sachs Group assumed coverage on shares of LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price for the company. Finally, Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, LifeStance Health Group currently has a consensus rating of “Moderate Buy” and an average price target of $12.12.

LifeStance Health Group Stock Up 1.6%

LFST opened at $12.42 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The company has a market capitalization of $4.82 billion, a PE ratio of 95.55 and a beta of 1.14. The stock’s fifty day moving average is $10.39 and its 200-day moving average is $8.22. LifeStance Health Group has a one year low of $4.77 and a one year high of $12.76.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company’s quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.01) earnings per share. On average, equities analysts predict that LifeStance Health Group will post 0.15 EPS for the current fiscal year.

Insider Activity

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 44,394 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the sale, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at approximately $2,684,789.10. This represents a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the completion of the transaction, the insider owned 98,101,407 shares of the company’s stock, valued at approximately $1,041,836,942.34. The trade was a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 14,629,850 shares of company stock valued at $154,952,012 over the last ninety days. Corporate insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFST. BlackRock Inc. acquired a new stake in LifeStance Health Group during the 2nd quarter valued at $389,293,000. Vanguard Group Inc. boosted its position in shares of LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after buying an additional 3,086,506 shares during the period. Silversmith Partners I GP LLC acquired a new stake in shares of LifeStance Health Group in the fourth quarter worth $100,842,000. Dimensional Fund Advisors LP grew its holdings in shares of LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after buying an additional 1,461,215 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of LifeStance Health Group by 38.5% during the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after buying an additional 2,843,388 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.